25063-68-7

Usage

Uses

Used in Medicinal Chemistry:
2,2-Dimethyl-5-(pyridin-3-ylaminomethylene)-[1,3]dioxane-4,6-dione is used as a building block or intermediate in the synthesis of pharmaceutical compounds, leveraging its heterocyclic nature and the potential biological activity associated with pyridine derivatives. Its unique structure allows for the development of new drugs with specific pharmacological properties.
Used in Organic Synthesis:
In the field of organic synthesis, 2,2-Dimethyl-5-(pyridin-3-ylaminomethylene)-[1,3]dioxane-4,6-dione serves as a versatile reactant or catalyst. Its reactivity and structural features make it suitable for use in various chemical reactions, contributing to the formation of complex organic molecules for a wide range of applications.
Used in Drug Development:
2,2-Dimethyl-5-(pyridin-3-ylaminomethylene)-[1,3]dioxane-4,6-dione is utilized in drug development as a potential candidate for the creation of new therapeutic agents. Its unique structure and the presence of the pyridine ring suggest that it may possess pharmacological properties that can be harnessed to treat various diseases or conditions.
Used in Chemical Research:
2,2-Dimethyl-5-(pyridin-3-ylaminomethylene)-[1,3]dioxane-4,6-dione is also used in chemical research to explore its reactivity, stability, and potential interactions with other molecules. This research can lead to a better understanding of the compound's properties and its possible applications in various chemical processes.

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 2033-24-1 cycl-isopropylidene malonate 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 53454-31-2 1,7-naphthyridin-4-ol 
• 5423-54-1 4-hydroxy-1,5-naphthyridine 
• 7689-63-6 4-chloro-1,5-naphthyridine 
• 79425-89-1 4-mercapto-1,5-naphthyridine 
• 16795-72-5 4-oxo-1,4-dihydro-1,5-naphthyridine 
• 5423-93-8 N¹,N¹-diethyl-N⁴-1,5-naphthyridin-4-ylpentane-1,4-diamine 

Relevant academic research and scientific papers

Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action

Ebola virus (EBOV) causes a deadly hemorrhagic fever in humans and non-human primates. There is currently no FDA-approved vaccine or medication to counter this disease. Here, we report on the design, synthesis and anti-viral activities of two classes of compounds which show high potency against EBOV in both in vitro cell culture assays and in vivo mouse models Ebola viral disease. These compounds incorporate the structural features of cationic amphiphilic drugs (CAD), i.e they possess both a hydrophobic domain and a hydrophilic domain consisting of an ionizable amine functional group. These structural features enable easily diffusion into cells but once inside an acidic compartment their amine groups became protonated, ionized and remain trapped inside the acidic compartments such as late endosomes and lysosomes. These compounds, by virtue of their lysomotrophic functions, blocked EBOV entry. However, unlike other drugs containing a CAD moiety including chloroquine and amodiaquine, compounds reported in this study display faster kinetics of accumulation in the lysosomes, robust expansion of late endosome/lysosomes, relatively more potent suppression of lysosome fusion with other vesicular compartments and inhibition of cathepsins activities, all of which play a vital role in anti-EBOV activity. Furthermore, the diazachrysene 2 (ZSML08) that showed most potent activity against EBOV in in vitro cell culture assays also showed significant survival benefit with 100% protection in mouse models of Ebola virus disease, at a low dose of 10 mg/kg/day. Lastly, toxicity studies in vivo using zebrafish models suggest no developmental defects or toxicity associated with these compounds. Overall, these studies describe two new pharmacophores that by virtue of being potent lysosomotrophs, display potent anti-EBOV activities both in vitro and in vivo animal models of EBOV disease.

TOLL-LIKE RECEPTOR 8 (TLR8)-SPECIFIC ANTAGONISTS AND METHODS OF MAKING AND USES THEREOF

Toll-like receptor 8 (TLR8)-specific inhibitors and methods of using the same in individuals having an autoimmune disease or an inflammatory disorder.

Discovery of an Inhibitor of the Proteasome Subunit Rpn11

The proteasome plays a crucial role in degradation of normal proteins that happen to be constitutively or inducibly unstable, and in this capacity it plays a regulatory role. Additionally, it degrades abnormal/damaged/mutant/misfolded proteins, which serves a quality-control function. Inhibitors of the proteasome have been validated in the treatment of multiple myeloma, with several FDA-approved therapeutics. Rpn11 is a Zn2+-dependent metalloisopeptidase that hydrolyzes ubiquitin from tagged proteins that are trafficked to the proteasome for degradation. A fragment-based drug discovery (FBDD) approach was utilized to identify fragments with activity against Rpn11. Screening of a library of metal-binding pharmacophores (MBPs) revealed that 8-thioquinoline (8TQ, IC50 value ～2.5 μM) displayed strong inhibition of Rpn11. Further synthetic elaboration of 8TQ yielded a small molecule compound (35, IC50 value ～400 nM) that is a potent and selective inhibitor of Rpn11 that blocks proliferation of tumor cells in culture.

INHIBITORS OF RPN11

Candidate compounds for specific inhibition of Rpn11 are represented by Formula 1a where each of R2, R3, R4, R5, R6, and R7 is independently selected from hydrogen (H), substituted and unsubstituted alkyl groups, carboxyl groups, or substituted and unsubstituted carboxyamides.

Hydroxynaphthyridine-derived group III metal chelates: Wide band gap and dee blue analogues of green Alq (tris(8-hydroxyquinolate)aluminum) and their versatile applications for organic light-emitting diodes

A series of group III metal chelates have been synthesized and characterized for the versatile application of organic light-emitting diodes (OLEDs). These metal chelates are based on 4-hydroxy-1,5naphthyridine derivates as chelating ligands, and they are